In the modern era of highly active antiretroviral therapy (HAART), which consists of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (PIs), reluctance to perform transplantation (Tx) in HIV-infected individuals is no longer justified (1, 2) . No fewer than 20-30% of HIV-positive patients are co-infected by HCV, and end-stage renal disease caused by HIV-associated nephropathy develops in as many as 5-10% of HAART-treated patients (2, 3) . As a result, HIV-positive patients are much more likely to receive needed liver or kidney Txs than are the HIV-negative. Recently, though, integrase inhibitors (INIs) have emerged. They are novel, potent anti-HIV drugs characterized by a distinct metabolic pathway; they include raltegravir (RAL, Isentress, Merck & Co., Inc., New Jersey, USA) and dolutegravir (DTG, S/GSK1349572, ViiV Healthcare/Shionogi, Middlesex,UK/Osaka, Japan) (4, 5) . Currently, their implications in the setting of Tx for HIV positive patients are being actively discussed.
To maintain undetectable plasma HIV-RNA, the current first line regimens of HAART consist of a PI boosted by ritonavir or a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs) as described above (2) . PIs and NNRTIs require metabolism by the cytochrome P450 family (2) . Ritonavir and the
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In the modern era of highly active antiretroviral therapy (HAART), reluctance to perform transplantation (Tx) in HIV-infected individuals is no longer justified. (6) . Such a complex scenario warrants development of HAART that exhibits no DDI with CNIs ( Figure 1 ). Integrase inhibitors (INIs) are mainly metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1. These INIs are neither inducers nor inhibitors of CYP3A4 (4, 5) . Therefore, they presumably do not interact with CNIs (2). RAL, a first generation INI, has been introduced into HIV-positive Tx mainly due to its distinct metabolic pathway and remarkable efficacy. PIsparing, RAL-based HAART does not require either dose adjustment of CNIs or discontinuation of HAART early post-Tx. There is increasing evidence that RAL is effective in preventing renal toxicity while maintaining potent and sustained antiretroviral properties (7, 8) (Figure 1 ). It has been reported that the negative impacts of abacavir sulfate/lamivudine (NRTIs)( Epzicom, ViiV healthcare,Middlesex,UK) on the kidney are smaller than those of tenofovir disoproxil fumarate/emtricitabine (NRTIs) (Truvada, Gilead Science, Inc., California, UAS) (2). Some researchers advocate that HAART regimens -RAL, a key drug, used with Epzicom as a backbone therapy -would be the best option for HIVpositive kidney Tx (2) (Figure 1 ).
DTG is a second generation INI (5). Its global phase III trials are currently in progress. During a phase II trial with HAART-naïve subjects, its non-inferior efficacy was demonstrated to be not inferior to that of efavirenz (NNRTI) (Sustiva, Bristol-Myers Squibb Pharma Company, New York, USA) (5) . In vitro studies have raised the curious possibility that DTG could have the potential of a higher genetic barrier to resistance than RAL, in the setting of INI-naïve patients (9) (Figure 1) . No serious drug-induced adverse effects were observed throughout phase II trials, and its tolerability was excellent (10) . A slight self-limiting serum creatinine (Cr) elevation was observed. An in vitro study strongly suggested that such a Cr elevation was merely a sequel to a non-pathologic decrease in Cr secretion via the proximal tube, but did not represent renal toxicity (5).
This accords well with a recent phase I study in which administration of DTG in healthy individuals did not negatively affect the glomerular filtration rate (GFR) (11) .
Once-daily DTG proved satisfactorily efficacious in the phase II trial for naïve subjects cited above, while RAL must be administered b.i.d. (4, 5) . This advantage may act in favor of using DTG (Figure 1 ). In support, a switch to (q.d.) modified release tacrolimus (Advagraf, Astellas Pharma Inc., Tokyo, Japan) from conventional b.i.d. (Prograf) increased using by Tx patients (12) . Of note, several cases of rabdomyolysis were observed in RAL-treated subjects. One must pay attention to concomitant use of RAL with other drugs (e.g. statins) that can cause rabdomyolysis (13) (14) (15) (16) (17) . In addition, one can not entirely exclude the possibility that the concern for rabdomyolysis caused by concomitant use of RAL and statins may be further enhanced by CNIs due to disturbance of statin uptake into the liver by organic anion transporting polypeptides (18) . On the other hand, one case of grade 4 CPK elevation was observed during phase II trials of DTG, but it was exercise-related, transient, and asymptomatic (10) . Even so, a caution is still needed before sufficient cases are accumulated during phase III trials and at post-market phase.
More accumulated experience using RAL is needed to fully understand the implications of INIs in HIVinfected Tx recipients. Meanwhile, the efficacy, safety, and tolerability of DTG must be carefully analyzed in comparison to those of RAL, PIs and NNRTIs during the phase III studies. Finally, the authors propose to discuss the possibility of using DTG in Tx, taking its attractive in vitro and in vivo characteristics into account. 
